Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 18/20 | 0.55 |
| ▸ | F3 | P13726 | 18/20 | 0.55 |
| ▸ | F2 | P00734 | 14/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846562 | 0.89 | F7 (0.60) | F7F3F2PRSS1 | |
| SCHEMBL5848346 | 0.80 | F7 (0.53) | F7F3F2PRSS1CFTR | |
| SCHEMBL5847557 | 0.79 | F7 (0.52) | F7F3F2PRSS1 | |
| SCHEMBL5848054 | 0.79 | F7 (0.67) | F7F3F2PRSS1 | |
| SCHEMBL23460607 | 0.75 | F7 (0.63) | F7F3F2PRSS1 | |
| SCHEMBL2145480 | 0.72 | F7 (0.65) | F7F3F2PRSS1 | |
| SCHEMBL3594973 | 0.72 | KDM4E (0.49) | F7F3F2HSD17B10 | |
| SCHEMBL25435320 | 0.68 | VNN1 (0.54) | MEN1USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL7027983 | 0.67 | F2 (0.56) | F7F3F2PRSS1 | |
| SCHEMBL3590750 | 0.67 | KDM4E (0.48) | F7F3F2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119094-B1 | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade | WARNER-LAMBERT COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1586565-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | Pharmacia Corporation (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6908919-B2 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1202975-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6664255-B1 | 1-alkylamido-3-amino substituted; inhibiting serine proteases | PHARMACIA CORPORATION | 2003-12-16 | — | — | US | disclosed |
| EP-1202975-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102448-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | F7 75/4885F3 18/4885F2 6/4885 |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | F7 62/4885F3 19/4885F2 6/4885 |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PRSS1, SERPINC1, SERPINE1 | F7 196/4885F3 100/4885F2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.